Evolus, Inc. (NASDAQ:EOLS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Evolus, Inc. (NASDAQ:EOLS) have been assigned an average rating of “Moderate Buy” from the five brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $21.25.

Several research analysts recently weighed in on EOLS shares. HC Wainwright cut their target price on shares of Evolus from $27.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Needham & Company LLC reissued a “hold” rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, August 6th. BTIG Research cut their target price on shares of Evolus from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Finally, Wall Street Zen cut Evolus from a “hold” rating to a “sell” rating in a report on Saturday, August 9th.

Evolus Trading Up 1.7%

Shares of EOLS stock opened at $6.51 on Friday. The firm has a 50-day moving average price of $9.03 and a 200 day moving average price of $10.98. Evolus has a twelve month low of $5.71 and a twelve month high of $17.82. The company has a market capitalization of $421.07 million, a price-to-earnings ratio of -6.64 and a beta of 1.12. The company has a current ratio of 2.27, a quick ratio of 1.86 and a debt-to-equity ratio of 22.00.

Insider Activity

In other Evolus news, Director Albert G. White III purchased 20,000 shares of the stock in a transaction on Monday, June 9th. The stock was bought at an average price of $9.45 per share, for a total transaction of $189,000.00. Following the acquisition, the director directly owned 50,378 shares of the company’s stock, valued at $476,072.10. This represents a 65.84% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, insider David Moatazedi sold 16,582 shares of Evolus stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $9.89, for a total value of $163,995.98. Following the completion of the sale, the insider owned 364,927 shares of the company’s stock, valued at $3,609,128.03. This trade represents a 4.35% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Evolus

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jump Financial LLC lifted its stake in shares of Evolus by 204.0% in the 2nd quarter. Jump Financial LLC now owns 355,568 shares of the company’s stock valued at $3,275,000 after purchasing an additional 238,586 shares in the last quarter. Diametric Capital LP acquired a new position in shares of Evolus in the 2nd quarter valued at about $148,000. Marshall Wace LLP acquired a new position in shares of Evolus in the 2nd quarter valued at about $625,000. Invesco Ltd. lifted its position in Evolus by 7.5% during the 2nd quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock worth $316,000 after acquiring an additional 2,383 shares in the last quarter. Finally, Quantbot Technologies LP lifted its position in Evolus by 15.4% during the 2nd quarter. Quantbot Technologies LP now owns 29,731 shares of the company’s stock worth $274,000 after acquiring an additional 3,971 shares in the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.